Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

作者：David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink, Joseph J. Eron, Yazdan Yazdanpanah, Daniel Podzamczer, Thomas A. Lutz, Jonathan Benjamin Angel, Gary J. Richmond, Bonaventura Clotet, Félix Gutiérrez, Louis M. Sloan, Marty St. Clair, Miranda I. Murray, Susan L. Ford, Joseph M. Mrus, Parul Patel, Herta M. Crauwels, Sandy K Griffith, Kenneth Sutton, David Dorey, Kimberly Y. Smith, Peter E Williams, William R. Spreen · 发表于：The Lancet · 年份：2017 · DOI：10.1016/s0140-6736(17)31917-7 · 被引用次数：506 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、HIV/AIDS Research and Interventions